Xenometrix Mutagenicity Assays and Cytotoxicity Screening Kits
Xenometrix produces and distributes today’s most advanced mutagenicity assays and cytotoxicity screening kits designed to help reduce hands-on time, test compound consumption, plastic waste and consequently the cost.
Xenometrix has been developing high quality Ames fluctuation test kits and cytotoxicity screening assays since 1995. Xenometrix offers full customer support free-of-charge, as well as fast customer compound testing with all assay systems.
AMES II, AMES MPF 98/100, AMES MPF 1535, AMES MPF 1537 FLUCTUATION ASSAYS
The Ames II, Ames MPF 98/100, Ames MPF 1535 and Ames MPF 1537 fluctuation assays are all modifications of the traditional Ames plate incorporation assay and the mini Ames test. The assay is performed entirely in liquid culture media in microplates and has a colorimetric readout.
The Ames II kit includes the S. typhimurium strains TA98 and TAMix (TA7001-TA7006) whereas the Ames MPF 98/100 kit includes TA98 and TA100. All kits contain the media necessary to perform the test. The assays are run in a liquid format on 384-wells plates and are automatable for high throughput screening.
The Ames II and the Ames MPF 98,100,1535,1537 kits use significantly (at least three-fold) less test compound than the traditional Ames, they all reduce hands-on-time and use six fold less plastic ware as compared to the traditional Ames tests. All S. typhimurium strains of Xenometrix are quality controlled (phenotyped and genotyped).
The Ames fluctuation assays are used by major pharmaceutical, chemical and cosmetic industries, but also by authorities analysing for environmental toxicants. Contract Service labs are also among our customers.
MULTIPLE ENDPOINTS: CYTOTOXICITY SCREENING KITS
The test kits are used in early screening to determine multiple cytotoxicity endpoints in eukaryotic cells. A full range of parameters is offered including: XTT, MTT, Lactate Dehydrogenase (LDH), Sulforhodamine B (SRB), Neutral Red (NR), Crystal Violet (CVDE), Acid Phosphatase (PAC) and Glucose (GLU). They allow the measurement of respiratory chain activity, membrane integrity, total protein synthesis, lysosomal activity, DNA content/cell number and metabolic activity.
The cytotoxicity screening kits allow you to determine up to four metabolic parameters from the same cellular sample. This technical optimization using multiple endpoints allows you to reduce test compound consumption and handling time. It further eliminates test-to-test variability due to potential variables such as passage number, time-since-plating, cell density, and medium age. Differences in IC50 values between assays therefore reflect more accurately the varying response of cellular functions to toxicants.
Using four sequential cytotoxicity tests greatly enhances chances to detect toxicants which might go unnoticed if only one assay were used. This becomes even more pronounced in experimental set-ups where only one exposure time is used. The combined kits also make optimal use of rare and valuable cell samples such as primary cells.
CELTOX SOFTWARE FOR THE DATA MANAGEMENT OF ASSAYS
Xenometrix offers the CelTox software to its customers free of charge. The software was developped for the data management, data processing and reporting of the assays. The IC50 and/or ID50 values and the linear regressions are calculated automatically and a detailed report serves as printout.
The cytotoxicity kits are used by major pharmaceutical, chemical and cosmetic industries, but also by authorities analysing for environmental toxicants. Contract Service labs are also among our customers.
Products and Services
Fujifilm Corporation and Merck, known as MSD outside the US and Canada, have announced that they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceutRead more
ARTES Biotechnology has announced its collaboration with Henkel in a joint three-year research programme that is granted by the German national BMBF (German Ministery of Education and Research) within the CLIB2021 cluster (Wettbewerb Industrielle Biotechnologie 2021). The cooperation aims to advaRead more
ARTES Biotechnology, which specializes in recombinant protein production from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary of Minapharm, jointly announced the start of a strategic collaboration to develop three therapeutic proteins. Financial details were not disclosed.Read more
ARTES Biotechnology GmbH expands technology platform Having achieved notable success with the Hansenula technology for years, the biotech company ARTES has now concluded an exclusive partnership with the internationally renowned Leibniz Institute of Plant Genetics and Crop PlantRead more
"We are looking forward to working with an international team“, says Dr Melanie Dröttboom, head of business development of Artes Biotechnology GmbH. Biotech company Artes, based near Düsseldorf, has been confirmed that it is developing an aptamer-based microarray forRead more
ACE Pharmaceuticals today announced that the first patient has entered the Phase III trial also known as the Levamisole trial. This trial was accepted by the EMEA by November 2006. The goal of this trial, which was accepted by the EMEA in November 2006, is to assess the efficacy and saRead more
ARTES announces the grant of the European patent on increasing recombinant protein secretion in yeast by co-expression of Calnexin, a protein responsible in intracellular quality control and sorting. In extensive studies, ARTES could show that overexpression of Calnexin results in signRead more
PROTEO Biotech AG and ARTES Biotechnology GmbH: Strategic Alliance for Marketing of Elafin in Asia, Africa and South America
Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc., USA, has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG / PROTEO Inc., in India, Egypt and ArgentinRead more